This is a review of the IMMerge trial looking at efficacy and safety of risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis.
The study involved over 300 patients from nine countries. Commentary is provided by Dr Saxon Smith, a consultant dermatologist in private practice in Gosford and St Leonards, Australia.
Please login below to download this issue (PDF)